It will restrict out-of-pocket costs for the product at $35 per ... also starting in 2024, bringing basal insulin product Lantus (insulin glargine) into line with the cap mandated on insulin ...

The average wholesale prices of the originator insulin are around $329 per vial ... FDA approval for a biosimilar product version of Lantus – Semglee – that is completely interchangeable ...

Despite this competition, prices have steadily climbed over the past decade, taking single or double-digit list price increases in a year. A 10 ml vial of Sanofi's long-acting insulin Lantus first ...

The French firm announced a $35 (£28) per month price cap on Lantus for ... up 90% of the US insulin market and have faced public backlash and political pressure to reduce costs of the drug.

The slow release variant of insulin called Glargine costs between Rs 410 and Rs 1,475 for a 10 ml vial. "So far we have expressed hepatitis B vaccine at laboratory scale level in fission yeast.